Tao Liang

Tao Liang

Auto-generated profile, based on publicly available information

Tao Liang

Department of Neurology Affiliated Hospital of Zunyi Medical University Zunyi China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2023 in Ibrain
Verified
Journal Article
Open access
ZLZhong Luo
Zhong Luo
PCPiao Cao
Piao Cao
JXJing‐Qing Xu
Jing‐Qing Xu
RYRong Yan
Rong Yan
JWJian Wang
Jian Wang
ZXZucai Xu
Zucai Xu
A 57‐year‐old man who suffered from a headache for 1 year, accompanied by blurred vision for 7 months and numbness in his left face for 1 week was admitted to the Affiliated Hospital of Zunyi Medical University on May 7, 2022. One year ago, the patient had no obvious precipitating factor of paroxysmal stabbing pain in the whole skull with dizziness, which could be relieved by oneself after lasting for 1–2 min each time, with about 20 episodes per day. The cranial magnetic resonance imaging revealed changes in bilateral frontal lobe ischemic foci, bilateral frontal, ethmoid, sphenoid and maxillary sinusitis, and retinal macular degeneration. After hormone shock treatment, the condition improved. He suffered from headaches again with blurred vision in the right eye 7 months ago and was initially diagnosed with multiple sclerosis. He then was discharged after improvement due to hormone shock therapy. Oral hormone therapy was continued outside the hospital, but he stopped it due to drug side effects (details remained unclear). After cutting off, he developed a headache and visited our hospital once more, the relevant tests were performed and the patient was diagnosed with idiopathic hypertrophic pachymeningitis (IHP). The symptoms were slightly abated after hormone therapy. We hope that through this case report, we can deepen the clinicians' understanding of IHP, and improve the diagnosis rate of the disease through relevant examinations in future clinical work, so that patients can receive timely treatment and the mental pressure and economic burden caused by the disease on patients are reduced.

28 October 2022 in Medicine
Verified
Journal Article
Open access
ZLZhong Luo
Zhong Luo
LZLinhai Zhang
Linhai Zhang
JYJuan Yang
Juan Yang
QZQing Hai Zhang
Qing Hai Zhang
TLTao Liang
Tao Liang
Rationale: Hereditary motor-sensory peripheral neuropathy, or Charot-Marie-Tooth (CMT) Charcot-Marie-Tooth disease is an inherited peripheral neuropathy characterized by progressive limb weakness and muscle atrophy. As the disease progresses, sensory and autonomic involvement may occur. We report a case of CMT associated with SOD1 gene mutation, in order to provide new ideas for clinical disease diagnosis. Patient concerns: A 50-years-old female patient was admitted to the hospital with “progressive weakness of the right lower extremity for 5 years, aggravating, and weakness of the left lower extremity for 4 months”. Diagnosis: The patient was diagnosed CMT. Intervention: Nerve nutrition and rehabilitation therapy were given, but the patient’s condition still did not improve significantly. Outcomes: The improvement of symptoms was not obvious. Lessons: The clinical manifestations and electromyography results of this patient are consistent with the characteristics of CMT. The peripheral nerve-related hereditary gene test found mutation in SOD1. It is possible that this mutation is linked to CMT. The disease is a neurodegenerative disease, that may be slowed by physical therapy and rehabilitation, but could not be healed.

12 January 2026 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
YYYufang Yang
Yufang Yang
TLTao Liang
Tao Liang
MZMingming Zhao
Mingming Zhao
HYHongxia Yang
Hongxia Yang
ZZZhilan Zhao
Zhilan Zhao
ZLZhong Luo
Zhong Luo
Background: Efgartigimod, a neonatal Fc receptor (FcRn) blocker, is approved for generalized Myasthenia Gravis (gMG), but predictors of early response are unclear. Using minimal symptom expression (MSE) as the therapeutic target, we developed and externally validated a clinical model to predict early MSE response after starting efgartigimod. This efgartigimod‐tailored model estimates the baseline probability of achieving early MSE and may assist in individualized treatment selection at therapy initiation. Methods: We retrospectively analyzed 118 adults with gMG treated at five tertiary centers in China (efgartigimod 10 mg/kg IV weekly ×4). MSE was defined as Myasthenia Gravis–Activities of Daily Living (MG‐ADL) ≤ 1 sustained ≥ 4 weeks; early MSE response was achievement within 4 weeks of initiation. Patients were split into a derivation cohort ( n = 64; three centers) and an external validation cohort ( n = 54; two centers). Candidate predictors included demographics, baseline severity, and laboratory indices. Variables associated with early MSE in univariable analyses entered multivariable logistic regression to construct a nomogram. Discrimination (AUC‐ROC), calibration (curves and Spiegelhalter Z ‐test), and clinical utility (decision curve analysis, DCA) were assessed, with bootstrap internal validation. Results: Early MSE response occurred in 26/64 derivation and 22/54 validation patients. Lower bulbar MG‐ADL (OR 0.633, p = 0.040), higher FVC% (OR 1.042, p = 0.048), and lower IgG (OR 0.795, p = 0.036) independently predicted early MSE response. The nomogram showed strong discrimination—derivation AUC 0.869 (95% CI 0.797–0.941), bootstrap AUC 0.880 (0.806–0.954), and external AUC 0.839 (0.760–0.919)—and good calibration (Spiegelhalter Z : 1.03, p = 0.303; 0.94, p = 0.347; 1.17, p = 0.242). DCA indicated net benefit across thresholds 0.05–0.82, with validation curves mirroring derivation. Conclusions: A three‐factor nomogram (bulbar MG‐ADL, FVC%, and serum IgG) provides an efgartigimod‐specific baseline estimate of early sustained‐MSE response probability, which may help neurologists select appropriate candidates, counsel expected benefit, and tailor follow‐up intensity or alternative escalation strategies. Trail Registration: Chinese Clinical Trial Registry (ChiCTR2500101971)

17 June 2022 in Ibrain
Verified
Journal Article
Closed access
ZLZhong Luo
Zhong Luo
JWJian Wang
Jian Wang
PCPiao Cao
Piao Cao
LZLin‐Hai Zhang
Lin‐Hai Zhang
RHRen‐Fang Hao
Ren‐Fang Hao
TLTao Liang
Tao Liang

13 February 2023 in Ibrain
Verified
Journal Article
Open access
ZLZhong Luo
Zhong Luo
PCPiao Cao
Piao Cao
CZChun‐Lin Zhang
Chun‐Lin Zhang
ZXZu‐Cai Xu
Zu‐Cai Xu
PXPing Xu
Ping Xu
TLTao Liang
Tao Liang
The incidence of incomplete partition Type I inner ear malformation is very low; therefore, bacterial meningitis caused by this malformation is also rare. Here, we report a case of such a patient. This case is a young female patient, who is 7 years old, began to have recurrent headaches, and after 5 years, also began to have chest and back pain. The doctor diagnosed meningitis, and the anti‐infection treatment was effective. She was followed up annually and continued to have outbreaks repeatedly for 17 years, but the cause of repeated infection was not found. After a detailed diagnosis and treatment in our hospital, the patient was finally diagnosed with incomplete partition Type I inner ear malformation, resulting in repeated bacterial meningitis. The patient recovered well after surgical treatment, and the symptoms did not recur after 1‐year follow‐up.

17 November 2023 in Medicine
Verified
Journal Article
Open access
CPChengyu Ma Pan
Chengyu Ma Pan
XYXiangrong Ma Yang
Xiangrong Ma Yang
ZTZhenzhen Tai
Zhenzhen Tai
ZZZhiwei Zhou
Zhiwei Zhou
RHRenfang Ma Hao
Renfang Ma Hao
TLTao Liang
Tao Liang
Rationale: Facial-onset sensory and motor neuronopathy (FOSMN) is a greatly rare disease, so far, autopsy evidence that is associated with neurodegenerative. Myasthenia gravis (MG) is an antibody-mediated and complement-involved acquired autoimmune disorder of the post-synaptic neuromuscular junction. There have been few reports about if there is related between the 2. In this study, we present the case of a man who was diagnosed as FOSMN with MG in continuity. Patient concerns: The patient chief complaints were right-side facial numbness and right-eyelid incomplete closure, followed by slurred speech and dysphagia, and the symptoms gradually progressed. The patient serum was positive for anti-AchR and anti-Titin antibodies. Diagnoses: The patient was diagnosed FOSMN with MG. Interventions: The patient symptoms were relieved after pyridostigmine bromide and prednisolone treatment. Outcomes: Symptoms have improved. Lessons: Facial-onset sensory and motor neuronopathy and MG have disparate clinical features. Therefore, we reported a rare case in which the 2 conditions concurrently existed. Immune dysfunction might be the pathogenesis of this association, while there is no definite evidence to support it, further studies are needed.